In the third quarter, Banyan Capital Management Inc. initiated a position in Johnson & Johnson, purchasing 3,853 shares valued at approximately $714,000 and making JNJ its 22nd largest holding at 0.3% of its portfolio. During the same period, Norges Bank established a new stake worth $4.88 billion, Laurel Wealth Advisors LLC increased its position by 15,040.6% to 7.42 million shares (valued at $1.13 billion), Vanguard Group Inc. added 3.09 million shares to reach 237.05 million shares ($36.21 billion), and Geode Capital Management LLC and Legal & General Group Plc expanded their holdings by 2.1% and 6.2% respectively, bringing Geode’s stake to 60.61 million shares ($9.23 billion) and L&G’s to 18.92 million shares ($2.89 billion). Institutional ownership of JNJ stands at 69.55%.

The European Committee for Medicinal Products for Human Use issued a positive opinion for AKEEGA, the combination of niraparib and abiraterone, targeting BRCA1/2-mutant metastatic hormone-sensitive prostate cancer. This opinion clears the path for an expanded oncology portfolio and could add a new multi-hundred-million-dollar annual revenue stream for Johnson & Johnson’s pharmaceuticals division, reinforcing expectations for mid-single-digit percentage growth in pharma sales for the upcoming fiscal year.

A flurry of upgrades has underscored buy-side confidence in JNJ’s near-term upside. Daiwa Capital Markets raised its target to $237 with an Outperform rating; Morgan Stanley upgraded to Overweight citing a stronger growth outlook; Scotiabank increased its target to $265 and reiterated Outperform after solid quarterly results; Citigroup lifted its target from $232 to $250 with a Buy rating; and Loop Capital set a $220 target. Among 26 analysts tracked by MarketBeat, one holds a Strong Buy rating, 17 have Buy ratings and eight maintain Hold ratings, yielding an average consensus target of $233.05 and a Moderate Buy consensus.

In the quarter ended January 21st, Johnson & Johnson reported revenue of $24.56 billion, up 9.1% year-over-year, and delivered earnings per share of $2.46, matching consensus estimates. Net margin reached 28.46%, and return on equity was 33.34%. The company reaffirmed its full-year guidance of $11.43–$11.63 EPS. On the capital return front, JNJ declared a quarterly dividend of $1.30 per share, payable March 10th to shareholders of record February 24th, representing a 2.3% yield and a 47.06% payout ratio.